<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239586</url>
  </required_header>
  <id_info>
    <org_study_id>2018/2388</org_study_id>
    <nct_id>NCT04239586</nct_id>
  </id_info>
  <brief_title>Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes</brief_title>
  <acronym>SUtoChildT1D</acronym>
  <official_title>Switching From Insulin to Sulfonylurea in Childhood and Adult Diabetes Due to Variants in the HNF1A, HNF4A, or HNF1B Genes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to switch from insulin to oral sulfonylurea in patients with
      apparent type 1 diabetes or maturity onset diabetes in the young that are insulin treated.
      The molecular cause will be DNA variants in the HNF1A, HNF4A, or HNF1B genes that are of
      unknown significance (VUS, class 3) or known to be pathogenic (class 4 and 5).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maturity onset diabetes in the young (MODY) is characterised by monogenic diabetes due to
      beta-cell dysfunction, with typical onset of diabetes before age of 25 years. There are 14
      known forms of MODY, ranging from rather common to extremely rare.

      About 1% of patients in the Norwegian Childhood Diabetes registry may have disease causing
      MODY mutations, according to a study recently published by the investigator's group and
      others.

      MODY associated mutations in the transcription factors HNF1A, HNF4A, and HNF1B leads to
      activation of the potassium channel causing depolarisation of the beta-cell membrane, which
      is crucial for excretion of insulin. By treating patients with HNF1A-MODY, HNF4A-MODY, and
      HNF1B-MODY with sulfonylurea class of drugs, these channels will close, causing
      depolarisation of the beta-cell membrane, and release of insulin. Hence, these patients can
      often stop insulin treatment when they are treated with sulfonylurea class drugs.

      Due to high throughput sequencing, a number of rare variants in these genes have been
      discovered. In many cases, bioinformatic tools are not sufficient to correctly classify these
      variants. In the present study, we intend to identify rare variants in the HNF1A, HNF4A, and
      HNF1B genes in patients with insulin dependent diabetes identified through the Norwegian
      Childhood Diabetes registry or the Norwegian MODY Registry with possibly disease causing
      HNF1A, HNF4A, or HNF1B mutations with sulfonylurea to see if they can reduce or even stop
      insulin treatment, and regulate their diabetes with sulfonylurea only. All variants will be
      investigated by bioinformatics tools as well as functional assays (tests for DNA-binding,
      transcriptional activation, nuclear localisation, protein expression). Primary endpoints are
      efficacy of sulfonylurea treatment measured by insulin requirement or not and level of HbA1c.
      Secondary endpoints are tolerance of sulfonylurea and effect on insulin secretion by oral and
      intravenous glucose tolerance tests. Bioinformatics and functional characterisation will be
      compared with success to reach primary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Switching insulin-treated diabetes patients with possibly disease causing mutations in HNF1A, HNF4A, or HNF1B to treatment with sulfonylurea.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of sulfonylurea treatment on insulin requirement measured in units insulin per kg per day</measure>
    <time_frame>5 years</time_frame>
    <description>Effect of sulfonylurea treatment on insulin requirement measured in units insulin per kg bodyweight per day, recorded at intervals of 3-6 months after exposure to sulfonylurea compared to before initiation of sulfonylurea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic control of diabetes measured by HbA1c in mmol/mol</measure>
    <time_frame>5 years</time_frame>
    <description>Metabolic control of diabetes measured by HbA1c in mmol/mol, recorded at intervals of 3-6 months after exposure to sulfonylurea compared to before initiation of sulfonylurea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of sulfonylurea dose in mg per kg per day</measure>
    <time_frame>5 years</time_frame>
    <description>Level of sulfonylurea dose in mg per kg body weight per day, recorded at intervals of 3-6 months after exposure to sulfonylurea compared to before initiation of sulfonylurea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of side effects of sulfonylurea</measure>
    <time_frame>5 years</time_frame>
    <description>Recording potential side effects of sulfonylurea, such as nausea, change in body weight, episodes of severe hypoglycemia, discolouration of teeth, diarrhoea, cardiovascular events, recorded at intervals of 3-6 months after exposure to sulfonylurea compared to before initiation of sulfonylurea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on endogenous insulin secretion assessed by intravenous glucose tolerance tests</measure>
    <time_frame>5 years</time_frame>
    <description>Maximum increment of serum insulin in nmol/L and serum c-peptide in pmol/L at intravenous glucose tolerance tests, recorded at intervals of 6-12 months after exposure to sulfonylurea compared to before initiation of sulfonylurea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on secretion of incretin hormones, assessed by oral glucose tolerance tests</measure>
    <time_frame>5 years</time_frame>
    <description>Maximum increment of serum insulin in nmol/L, serum c-peptide in pmol/L and incretins (GIP in pmol/L and GLP-1 in pmol/L) at oral glucose tolerance tests and in comparison with intravenous gluclose tolerance tests, recorded at intervals of 6-12 months after exposure to sulfonylurea compared to before initiation of sulfonylurea</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Maturity-Onset Diabetes of the Young, Type 3</condition>
  <condition>Maturity Onset Diabetes of the Young, Type 1</condition>
  <condition>Childhood Diabetes Mellitus</condition>
  <condition>Insulin-dependent Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sulfonylurea treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing doses of sulfonylurea class of drug to see whether insulin treatment can be reduced in dose or stopped.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylurea</intervention_name>
    <description>Starting treatment with sulfonylurea class of drug</description>
    <arm_group_label>Sulfonylurea treatment group</arm_group_label>
    <other_name>Glibenclamide</other_name>
    <other_name>Glipizide</other_name>
    <other_name>Glimerepiride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes and DNA sequence variant of unknown significance (VUS, class 3) or pathogenic
             (class 4, and 5) in the HNF1A, HNF4A, or HNF1B genes

          -  On insulin treatment

          -  Willing and able to provide informed consent (parents if younger than 16 years of age)

        Exclusion Criteria:

          -  Known anaphylactic response to sulfonylurea

          -  Diabetes and DNA sequence variant in the HNF1A, HNF4A, or HNF1B genes that are known
             to be non-pathogenic (class 1-2)

          -  Not willing or able to provide informed consent (parents if younger than 16 years of
             age)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pål R. Njølstad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics and Adolescents, Haukeland University Hospital, and Department of Clinical Science, Faculty of Medicine, University of Bergen</name>
      <address>
        <city>Bergen</city>
        <zip>NO-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njølstad PR, Ashcroft FM, Hattersley AT. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004 Apr 29;350(18):1838-49. Erratum in: N Engl J Med. 2004 Sep 30;351(14):1470.</citation>
    <PMID>15115830</PMID>
  </reference>
  <reference>
    <citation>Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, Abuelo D, Phornphutkul C, Molnes J, Bell GI, Gloyn AL, Hattersley AT, Molven A, Søvik O, Njølstad PR. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes. 2004 Oct;53(10):2713-8.</citation>
    <PMID>15448106</PMID>
  </reference>
  <reference>
    <citation>Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006 Aug 3;355(5):467-77.</citation>
    <PMID>16885550</PMID>
  </reference>
  <reference>
    <citation>Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT; Neonatal Diabetes International Collaborative Group. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 2008 Feb;31(2):204-9. Epub 2007 Nov 19.</citation>
    <PMID>18025408</PMID>
  </reference>
  <reference>
    <citation>Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet. 1997 Jan;15(1):106-10.</citation>
    <PMID>8988180</PMID>
  </reference>
  <reference>
    <citation>Njølstad PR, Søvik O, Cuesta-Muñoz A, Bjørkhaug L, Massa O, Barbetti F, Undlien DE, Shiota C, Magnuson MA, Molven A, Matschinsky FM, Bell GI. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med. 2001 May 24;344(21):1588-92.</citation>
    <PMID>11372010</PMID>
  </reference>
  <reference>
    <citation>Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006 Aug 3;355(5):456-66.</citation>
    <PMID>16885549</PMID>
  </reference>
  <reference>
    <citation>Johansson BB, Irgens HU, Molnes J, Sztromwasser P, Aukrust I, Juliusson PB, Søvik O, Levy S, Skrivarhaug T, Joner G, Molven A, Johansson S, Njølstad PR. Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry. Diabetologia. 2017 Apr;60(4):625-635. doi: 10.1007/s00125-016-4167-1. Epub 2016 Dec 2.</citation>
    <PMID>27913849</PMID>
  </reference>
  <reference>
    <citation>Irgens HU, Molnes J, Johansson BB, Ringdal M, Skrivarhaug T, Undlien DE, Søvik O, Joner G, Molven A, Njølstad PR. Prevalence of monogenic diabetes in the population-based Norwegian Childhood Diabetes Registry. Diabetologia. 2013 Jul;56(7):1512-9. doi: 10.1007/s00125-013-2916-y. Epub 2013 Apr 27.</citation>
    <PMID>23624530</PMID>
  </reference>
  <reference>
    <citation>Najmi LA, Aukrust I, Flannick J, Molnes J, Burtt N, Molven A, Groop L, Altshuler D, Johansson S, Bjørkhaug L, Njølstad PR. Functional Investigations of HNF1A Identify Rare Variants as Risk Factors for Type 2 Diabetes in the General Population. Diabetes. 2017 Feb;66(2):335-346. doi: 10.2337/db16-0460. Epub 2016 Nov 29.</citation>
    <PMID>27899486</PMID>
  </reference>
  <reference>
    <citation>Hattersley AT, Greeley SAW, Polak M, Rubio-Cabezas O, Njølstad PR, Mlynarski W, Castano L, Carlsson A, Raile K, Chi DV, Ellard S, Craig ME. ISPAD Clinical Practice Consensus Guidelines 2018: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2018 Oct;19 Suppl 27:47-63. doi: 10.1111/pedi.12772.</citation>
    <PMID>30225972</PMID>
  </reference>
  <reference>
    <citation>Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, Tessmann EH, Juliusson PB, Skrivarhaug T, Pearson ER, Flanagan SE, Babiker T, Thomas NJ, Shepherd MH, Ellard S, Klimes I, Szopa M, Polak M, Iafusco D, Hattersley AT, Njølstad PR; Neonatal Diabetes International Collaborative Group. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes Endocrinol. 2018 Aug;6(8):637-646. doi: 10.1016/S2213-8587(18)30106-2. Epub 2018 Jun 4. Erratum in: Lancet Diabetes Endocrinol. 2018 Sep;6(9):e17.</citation>
    <PMID>29880308</PMID>
  </reference>
  <reference>
    <citation>Sagen JV, Bjørkhaug L, Haukanes BI, Grevle L, Molnes J, Nedrebø BG, Søvik O, Njølstad PR, Johansson S, Molven A. The HNF1A mutant Ala180Val: Clinical challenges in determining causality of a rare HNF1A variant in familial diabetes. Diabetes Res Clin Pract. 2017 Nov;133:142-149. doi: 10.1016/j.diabres.2017.08.001. Epub 2017 Sep 1.</citation>
    <PMID>28934671</PMID>
  </reference>
  <reference>
    <citation>Flannick J, Johansson S, Njølstad PR. Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes. Nat Rev Endocrinol. 2016 Jul;12(7):394-406. doi: 10.1038/nrendo.2016.50. Epub 2016 Apr 15. Review.</citation>
    <PMID>27080136</PMID>
  </reference>
  <reference>
    <citation>Balamurugan K, Bjørkhaug L, Mahajan S, Kanthimathi S, Njølstad PR, Srinivasan N, Mohan V, Radha V. Structure-function studies of HNF1A (MODY3) gene mutations in South Indian patients with monogenic diabetes. Clin Genet. 2016 Dec;90(6):486-495. doi: 10.1111/cge.12757. Epub 2016 Mar 4.</citation>
    <PMID>26853433</PMID>
  </reference>
  <reference>
    <citation>Flannick J, Beer NL, Bick AG, Agarwala V, Molnes J, Gupta N, Burtt NP, Florez JC, Meigs JB, Taylor H, Lyssenko V, Irgens H, Fox E, Burslem F, Johansson S, Brosnan MJ, Trimmer JK, Newton-Cheh C, Tuomi T, Molven A, Wilson JG, O'Donnell CJ, Kathiresan S, Hirschhorn JN, Njølstad PR, Rolph T, Seidman JG, Gabriel S, Cox DR, Seidman CE, Groop L, Altshuler D. Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet. 2013 Nov;45(11):1380-5. doi: 10.1038/ng.2794. Epub 2013 Oct 6.</citation>
    <PMID>24097065</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Maturity onset diabetes in the young</keyword>
  <keyword>Childhood diabetes</keyword>
  <keyword>Type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
    <mesh_term>Glipizide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD that underlie the results in the planned publications. The IPD will be summary data, and with no personal identifiers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>6 months after the planned publications are finally accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>IPD will be shared after written request and consideration to the corresponding author of the respective publication. Data will be shared with researchers in the same or similar field only. IPD will include summary data without personal identity and Describe by what access criteria IPD and any additional supporting information will be shared, including with whom, for what types of analyses, and by what mechanism. The corresponding and first authors will review requests and criteria for reviewing requests may also be provided.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

